Pediapharm (fka )

[BioSpecialist]

2 Approvals around the corner = 300-500% upside Potential here

Rupafin approval in August will push this unknown low float gem 100% and higher .Another Approval (Otixal) is expected in November . Market Cap of $10.8 Million is ridiculous for this great Company especially when the Cash blance is over $7 Million .Get some before they get the Approval .GL



Pediapharm (PDP.V)

Market Cap: c$10.8 Million
Cash: c$7.5 Million
Price 0.15

Presentation
http://pedia-pharm.com/wp-content/themes/ifeature-tpl/PDF/Pediapharm-Corporate-Presentation-MARCH-2016-v4-WEBSITE-PDF.pdf

2 Health Canada approval:Rupafin(Aug-Sept 2016) and Otixal (Nov-Dec 2016)


Rupatadine’s estimated launch is now estimated to be in the period of July-September 2016 vs October-December 2016 as previously stated due to the fact the Company now estimates it will receive Health Canada’s approval by August 2016.

PRODUCT INDICATION MARKET SIZE (CDN $) EST. ANNUAL PEAK SALES (CDN$) EST. LAUNCH DATE

Rupatadine(Rupafin) Antihistamine (RX Indication) 120M 6M Q-3 2016

Cetraxal-Plus (Otixal) Ear Infection, Swimmer’s Ear 25M 4M Q-4 2016